You are here: Industry Insights > Tecentriq

News List

FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer worldpharmanews
March 21, 2019
Roche announced that FDA approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
FDA OKs Tecentriq for Extensive-Stage Small Cell Lung Cancer drugs
March 20, 2019
Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer.
Roche’s Tecentriq notches win in breast cancer with US approval expressbpd
March 14, 2019
The FDA’s OK was based on a trial that showed the drug cocktail helped stave off the disease’s advance by a median 7.4 months, compared to 4.8 months with chemotherapy
Roche gets first checkpoint inhibitor OK in breast cancer pharmaphorum
March 12, 2019
Roche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first in class to be approved for any form of breast cancer
Roche's Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer biospectrumasia
March 11, 2019
Roche's Genentech unit on Friday announced that the FDA granted accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy for use in adults with PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast ca
Immatics, Roche ally to trial Tecentriq with cell therapy fiercebiotech
February 27, 2019
Immatics has struck a deal to test its autologous cell therapy in combination with Roche’s checkpoint inhibitor Tecentriq. The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors....
FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) worldpharmanews
January 22, 2019
Roche announced that the US Food and Drug Administration has accepted the company's supplemental Biologics License Application for Tecentriq
Early access to Tecentriq combination granted through EAMS pharmatimes
January 03, 2019
UK patients with a form of advanced lung cancer will soon be able to access the immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab), carboplatin and paclitaxel chemotherapy through.
FDA agrees to review Roche’s Tecentriq combination for breast cancer pharmaceutical-technology
December 18, 2018
The US Food and Drug Administration (FDA) has accorded priority review status to the supplemental biologics licence application (sBLA) of Roche’s Tecentriq (atezolizumab) as a combination therapy for breast cancer......
Roche’s lung cancer combo treatment wins FDA approval expressbpd
December 11, 2018
The approval was based on results from a late-stage study, which showed the Tecentriq regimen helped patients with metastatic non-squamous non-small cell lung cancer (NSCLC)

Previous page 1 2 3 4 5 6 7 Next page